Skip to main content

Table 1 Costs of treatment for anemia of chronic kidney disease, by disease stage, prior to SEB introduction

From: A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

Treatment strategies for anemia of CKD by disease stage

Drug cost per defined daily dose ($)

Average dose per week

Treatment cost per patient per week ($)

Annual treatment cost per patient ($)

Stage III/IV short acting ESA (SC)

14.25

4,186 IU

59.65

3,101.83

Stage III/IV long acting ESA (SC)

13.36

21 mcg

62.05

3,226.59

Stage V short acting ESA (SC)

14.25

8,033 IU

114.47

5,952.45

Stage V long acting ESA (SC)

13.36

27 mcg

79.27

4,122.01

Stage V short acting ESA (IV)

14.25

11,475 IU

163.52

8,502.98

Stage V long acting ESA (IV)

13.36

38 mcg

113.71

5,912.84

  1. SEB = subsequent entry biologic; CKD = chronic kidney disease; ESA = erythropoiesis stimulating agents; SC = subcutaneous; IV = intravenous; IU = international units; mcg = micrograms.